Clinical research
The company presented the data at the American Society of Clinical Oncology Virtual Scientific Program and also published data simultaneously in the New England Journal of Medicine.
The main Phase I monotherapy study had a favorable safety profile, showing that Ad+V was safely administered and tolerably in both craniotomy and stereotactic subjects.
The data, which was presented at the American Society of Clinical Oncology annual meeting, looked into the use of ALLO-501 for relapsed/refractory non-Hodgkin lymphoma.
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
Ironwood and AbbVie said a Phase II trial assessing the drug candidate MD-7246, a delayed-release formulation of Linzess, did not meet its primary or key secondary endpoints.
The company is presenting the study of Tagrisso during the plenary session of the American Society of Clinical Oncology ASCO20 Virtual Scientific Program on Sunday, May 31.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.
ViralClear Chief Executive Officer Nick Spring told BioSpace that the preclinical work is “telling a very good story.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 29, 2020.
The Phase II study will be performed in collaboration with the National Institutes of Health under a $2.7 million grant.
PRESS RELEASES